Therapeutic Management and Long-Term Outcome of Hyperthyroidism in Patients with Antithyroid-Induced Agranulocytosis: A Retrospective, Multicenter Study
Authors:
- Carlos García GómezCGCarlos García Gómez
- Elena NavarroENElena Navarro
- Victoria AlcázarVAVictoria Alcázar
- Antonio López-GuzmánALAntonio López-Guzmán
- Francisco ArrietaFAFrancisco Arrieta
- Emma AndaEAEmma Anda
- Betina BiagettiBetina Biagetti
- Fernando Guerrero-PérezFGFernando Guerrero-Pérez
- Carles VillabonaCVCarles Villabona
- Andrés Ruiz de Assín ValverdeAVAndrés Ruiz de Assín Valverde
- Cristina LamasCLCristina Lamas
- Beatriz LecumberriBLBeatriz Lecumberri
Open Access
- 16 October 2023
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (20) , 6556
Abstract
Background: Antithyroid drug-induced agranulocytosis (AIA) (neutrophils n = 21), amiodarone-induced thyrotoxicosis (n = 7), and hyperfunctioning multinodular goiter (n = 1). Twenty-one patients were treated with methimazole, as well as six patients with carbimazole and two patients with propylthiouracil. Results: The median (IQR) time to development of agranulocytosis was 6.0 (4.0–11.5) weeks. The most common presenting sign was fever accompanied by odynophagia. All of the patients required admission, reverse isolation, and broad-spectrum antibiotics; moreover, G-CSF was administered to 26 patients (89.7%). Twenty-one patients received definitive treatment, thirteen patients received surgery, nine patients received radioiodine, and one of the patients required both treatments. Spontaneous normalization of thyroid hormone values occurred in six patients (four patients with amiodarone-induced thyrotoxicosis and two patients with Graves’ disease), and two patients died of septic shock secondary to AIA. Conclusions: AIA is a potentially lethal complication that usually appears around 6 weeks after the initiation of antithyroid therapy. Multiple drugs are required to control hyperthyroidism before definitive treatment; additionally, in a significant percentage of patients (mainly in those treated with amiodarone), hyperthyroidism resolved spontaneously.Keywords
This publication has 31 references indexed in Scilit:
- Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical EndocrinologistsThyroid®, 2011
- The role of haematopoietic growth factors granulocyte colony‐stimulating factor and granulocyte‐macrophage colony‐stimulating factor in the management of drug‐induced agranulocytosisBritish Journal of Haematology, 2010
- Methimazole-Induced Agranulocytosis in Patients with Graves' Disease Is More Frequent with an Initial Dose of 30 mg Daily than with 15 mg DailyThyroid®, 2009
- Repercusiones del tratamiento con amiodarona sobre la función tiroidea y su manejo actualEndocrinología y Nutrición, 2007
- Antithyroid DrugsNew England Journal of Medicine, 2005
- Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoringArchives of internal medicine (1960), 1990
- METHIMAZOLE‐INDUCED AGRANULOCYTOSIS IN JAPANESE PATIENTS WITH GRAVES’ DISEASEClinical Endocrinology, 1989
- Risk of agranulocytosis and aplastic anaemia in relation to use of antithyroid drugs. International Agranulocytosis and Aplastic Anaemia Study.BMJ, 1988
- Agranulocytosis induced by propylthiouracil: evidence of a drug dependent antibody reacting with granulocytes, monocytes and haematopoietic progenitor cellsBritish Journal of Haematology, 1986
- Thyroid Function after Surgical Treatment of ThyrotoxicosisNew England Journal of Medicine, 1978